NPC1L1 Inhibitors
4 drugsAbout NPC1L1
NPC1L1, or Niemann-Pick C1-Like 1, is a key protein that mediates intestinal absorption of cholesterol. By controlling cholesterol uptake, NPC1L1 plays a central role in maintaining cholesterol homeostasis. This makes it an important drug target for managing cholesterol levels and related metabolic disorders.
Human genetic studies provide strong validation for NPC1L1 as a therapeutic target, with variants linked to hypercholesterolemia (score 0.82) and metabolic disease (score 0.80). Loss-of-function variants are protective against hypercholesterolemia, supporting inhibition-based therapies. There are also 20 strong eQTL/pQTL signals.
NPC1L1 is targeted by 4 FDA-approved small molecule drugs, including ZETIA, VYTORIN, and NEXLIZET. These drugs are developed by Merck, ESPERION THERAPS INC, and GLENMARK PHARMS LTD, primarily for metabolic indications. The first drug was approved in 2002, and the most recent in 2020.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Lipidemia with only 2 trials.
Human Genetic Evidence Strong
NPC1L1 has strong genetic support with a max score of 0.82 linking it to hypercholesterolemia.
Strong genetic support increases the likelihood of clinical success, warranting further investment.
💡 Why inhibition?
- • Loss-of-function variants reduce disease risk (OR < 1)
- • 100% directional consistency across 2 traits
- • Strong signal in phenotype, nutritional or metabolic disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
14 totalGWAS and other genetic studies link NPC1L1 to 14 diseases.
Inhibiting this target may be therapeutic
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for NPC1L1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Three companies, including Merck and ESPERION THERAPS INC, have approved drugs targeting NPC1L1.
The market is moderately concentrated, suggesting potential for new entrants with differentiated therapies.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| NEXLIZET | ESPERION THERAPS INC | 2020 | 2 |
Drug Modality Landscape
Modalities
Routes of Administration
NPC1L1 is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Clinical Trials 345 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 96 | 86 | 7 | 3 | 92% |
| Phase 2 | 72 | 55 | 10 | 7 | 85% |
| Phase 3 | 92 | 70 | 11 | 10 | 86% |
| Phase 4 | 85 | 52 | 11 | 21 | 83% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved NPC1L1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting NPC1L1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2002 - 2020)
Atherosclerotic Vascular Disease
The approval timeline for NPC1L1-targeting drugs spans 19 years, from 2002 to 2020.
The recent approval of NEXLIZET in 2020 indicates continued interest and potential for further drug development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 174 clinical trials targeting NPC1L1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities